



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 43826-0003 US	APPLICATION NUMBER 10/759,878
	FIRST NAMED INVENTOR REICH et al.	
	FILING DATE January 16, 2004	ART UNIT 1635

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT****U.S. PATENT DOCUMENTS**

EXAMINER INITIALS	Cite No.	DOCUMENT NUMBER	PUBLICATION DATE (MM/DD/YYYY)	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
		Number-Kind Code (if known)			
TCG	A	2002/0086356 A1	07/04/2002	TUSCHL et al.	
TCG	B	2002/0132788 A1	09/19/2002	LEWIS et al.	
TCG	C	2002/0162126 A1	10/31/2002	BEACH et al.	
TCG	D	2002/0173478 A1	11/21/2002	GEWIRTZ	
TCG	E	6,506,559	11/14/2003	FIRE al.	
TCG	F	6,177,401	01/23/2001	ULLRICH et al.	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS	Cite No.	FOREIGN PATENT DOCUMENT	PUBLICATION DATE (MM/DD/YYYY)	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
		Country Code-Number- Kind Code (if known)				
TCG	G	CA 2359180	08/03/2000	KREUTZER et al.		
TCG	H	WO03/099298A1	12/04/2003	Maxplanck Gesellschaft Zur Forderung Der Wissenschaften E.V. et al.		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (In CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
TCG	I	Bennett et al., <i>Hum Gene Ther</i> 10:1763-1769 (abstract) (Sept. 1996)	
TCG	J	Elbashir et al., <i>Nature</i> , 411:494-498 (24 May 2001)	
TCG	K	Elbashir et al., <i>Genes & Development</i> 15:188-200 (2001)	
TCG	L	Erickson, D., "RNAi Revs Up", <i>Start-Up</i> (A#2002900168) pp. 1-12 (Oct. 2002)	
EXAMINER SIGNATURE		/Terra Cotta Gibbs/	DATE CONSIDERED 08/18/2006
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE U.S. PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	ATTY. DOCKET NO. 43826-0003 US	APPLICATION NUMBER 10/759,878
	FIRST NAMED INVENTOR REICH et al.	
	FILING DATE January 16, 2004	ART UNIT 1635

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Publisher, city and/or country where published	T
TCG	M	Fire et al., <i>Nature</i> , 391:806-811 (19 Feb. 1998)	
	N	Holash et al., <i>PNAS</i> , 99(17):11393-11398 (Aug. 20, 2002)	
	O	Kim et al., <i>PNAS</i> , 99(17):11399-11404. (Aug. 20, 2002)	
	P	Miyamoto et al., "Vascular endothelial Growth Factor (VEGF)-Induced Retinal Vascular Permeability is mediated by Intercellular Adhesion Molecule-1 (ICAM-1)", <i>American Journal of Pathology</i> 156(5):1733-1739 (May 2000)	
	Q	Miyamoto et al., "Prevention of Leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition", <i>Proc. Natl. Acad. Sci USA</i> 96:10836-10841 (September 1999)	
	R	Moromizato et al., "CD18 and ICAM-1-Dependent Corneal Neovascularization and Inflammation after Limbal Injury", <i>American Journal of Pathology</i> 157(4) (October 2000)	
	S	Novina et al., <i>Nature Medicine</i> , 8(7):81-686 (July 2002)	
	T	Sakurai et al., "Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization", <i>Invest. Ophthalmol Vis. Sci.</i> 44(6):2743-9 (2003) ABSTRACT ONLY	
	U	Tischer et al., <i>J. Biol Chem</i> 266:11947-11954 (abstract) (June 25, 1991)	
	V	Tuschl, T., The siRNA user guide (revised October 11, 2002), Accessed from http://www.mpibpc.gwdg.de/abteilungen/100/105/sima.html on 11/1/2002.	
	W	Tuschl, T., <i>Nat. Biotech</i> 20: 446-448 (May 2002)	
	X	Van Brunt, J., <i>Signals Magazine</i> : "Buzz – Shoot the Messenger" 08/22/2002, Accessed from http://www.signalsmag.com/signalsmag.../3DF5AEF6049CC81C99256C1D0055BAA on 10/28/2002.	
	Y	Wu et al., <i>Mol Cell Biol</i> , Vol. 22:22: 7758-7768 (abstract) (Nov. 2002)	
TCG	Z	Xia et al., <i>Nature Biotechnology</i> , Vol. 20:1006-1010 (Oct. 2002)	
EXAMINER SIGNATURE		/Terra Cotta Gibbs/	DATE CONSIDERED
			08/18/2006
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			



Substitute form 1449 PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		
				Application Number	10/759,878	
				Filing Date	January 16, 2004	
				First Named Inventor	Reich	
				Group Art Unit	1635	
				Examiner Name	Not Yet Assigned Gibbs	
Sheet	1	of	1	Attorney Docket Number		129402.00701
U.S. PATENT DOCUMENTS						
Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
TCG	AA	6,015,894		Bennet et al.	01-18-2000	
FOREIGN PATENT DOCUMENTS						
Examiner's Initials	Cite No.	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office	Number Kind Code (if known)			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)						
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or county where published.				
TCG	CA	KATZ et al., ICAM-1 Antisense Oligodeoxynucleotide Improves Islet Allograft Survival and Function, 2000, Cell Trans. 9:817-828				
TCG	CB	DRAGUN et al., ICAM-1 antisense oligodesoxynucleotides prevent reperfusion injury and enhance immediate graft function in renal transplantation, 1998, Kidney Inter. 54:590-602				
TCG	CC	ELBASHIR et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, 2001, Nature 411:494-498				
TCG	CD	AGRAWAL et al., Antisense therapeutics: is it as simple as complementary base recognition?, 2000, Mol. Med. Today 6:72-81				
TCG	CE	JEN et al., Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies, 2000, Stem Cells 18:307-319				
TCG	CF	COBURN et al., siRNAs: a new wave of RNA-based therapeutics, 2003, J. Antimicrobial Chemotherapy 51:753-756				
TCG	CG	CAPLEN, RNAi as a gene therapy approach, 2003, Expert Opin. Biol. Ther. 3(4):575-586				
TCG	CH	AGAMI, RNAi and related mechanisms and their potential use for therapy, 2002, Curr. Op. Chem. Biol. 6:829-834				
Examiner Signature	/Terra Cotta Gibbs/			Date Considered	08/18/2006	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.